Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' NowZacks Investment Research • 12/13/22
Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development SummitGlobeNewsWire • 11/28/22
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business UpdateGlobeNewsWire • 11/14/22
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLDGlobeNewsWire • 11/01/22
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck CancerGlobeNewsWire • 10/12/22
Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisGlobeNewsWire • 10/06/22
Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022GlobeNewsWire • 09/08/22
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business UpdateGlobeNewsWire • 08/15/22
Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024GlobeNewsWire • 07/26/22
Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022GlobeNewsWire • 06/21/22
Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH CongressGlobeNewsWire • 05/23/22
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business UpdateGlobeNewsWire • 05/16/22
Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisGlobeNewsWire • 04/14/22
Galectin Therapeutics Reports 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/22
Galectin Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceGlobeNewsWire • 01/06/22
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. UihleinGlobeNewsWire • 12/21/21
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual MeetingGlobeNewsWire • 12/13/21
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business UpdateGlobeNewsWire • 11/15/21
UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLDGlobeNewsWire • 11/05/21
Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting™ 2021, Hosted by the AASLDGlobeNewsWire • 10/27/21
UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021GlobeNewsWire • 10/05/21
Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 10/05/21
Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewsWire • 09/09/21